CSL Limited operates in the Commercial physical research sector. CSL Limited is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and develops plasma products. Intellectual Property Licensing includes revenue and associated expenses from the licensing of Intellectual Property generated by the Company to unrelated third parties. Other Human Health consists of CSL Bioplasma and CSL Biotherapies. The Company operates in four geographic areas: Australia, the United States of America, Switzerland, and Germany. In December 2010, the United States Food and Drug Administration (FDA) approved GARDASIL. On February 18, 2011 CSL Behring announced the United States FDA had granted marketing approval for Corifact Factor XIII concentrate (Human) for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. In our complete report available for purchase the company is compared to: Sigma Pharmaceuticals Limited, Hospira, Incorporated and Celgene Corporation.